IL-17A, a possible biomarker for the evaluation of treatment response in Trypanosoma cruzi infected children: A 12-months follow-up study in Bolivia

IL-17A 是评估克氏锥虫感染儿童治疗反应的可能生物标志物:玻利维亚的一项为期 12 个月的随访研究

阅读:13
作者:Clara Vásquez Velásquez, Graciela Russomando, Emilio E Espínola, Zunilda Sanchez, Kota Mochizuki, Yelin Roca, Jimmy Revollo, Angelica Guzman, Benjamín Quiroga, Susana Rios Morgan, Roberto Vargas Ortiz, Alberto Zambrana Ortega, Eida Espinoza, Juan Eiki Nishizawa, Mohamed Gomaa Kamel, Mihoko Kikuchi, 

Background

The National Program for Chagas disease was implemented in Bolivia in 2006, and it greatly decreased the number of infections through vector control. Subsequently, a treatment regimen of benznidazole (BNZ) was started in seropositive school-age children living in certified vector control areas.

Conclusions

Plasma levels of IL-17A might be a bio-marker for detecting persistent infection of T. cruzi and its chronic inflammation.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。